| 张淑兰,马力文,张照辉,等.153Sm-EDTMP治疗多发性骨转移癌的临床观察[J].中华放射医学与防护杂志,2006,26(2):163-165.ZHANG Shu-lan,MA Li-wen,ZHANG Zhao-hui,et al.Clinical observation of multiple metastatic bone cancer by ~153Sm-EDTMP[J].Chin J Radiol Med Prot,2006,26(2):163-165 |
| 153Sm-EDTMP治疗多发性骨转移癌的临床观察 |
| Clinical observation of multiple metastatic bone cancer by ~153Sm-EDTMP |
| 投稿时间：2005-12-28 |
| DOI： |
| 中文关键词: 153Sm-2乙二胺四甲基膦酸 骨转移癌 生活质量 造血功能 |
| 英文关键词:153Sm-EDTMP Metastatic Bone cancer Life quality Hemapoietic function |
| 基金项目: |
| 作者 | 单位 | | 张淑兰 | 100083, 北京大学第三医院肿瘤治疗中心肿瘤化疗放射病科, | | 马力文 | 100083, 北京大学第三医院肿瘤治疗中心肿瘤化疗放射病科, | | 张照辉 | 100083, 北京大学第三医院肿瘤治疗中心肿瘤化疗放射病科, | | 李惠平 | 100083, 北京大学第三医院肿瘤治疗中心肿瘤化疗放射病科, | | 贾廷珍 | 100083, 北京大学第三医院肿瘤治疗中心肿瘤化疗放射病科, |
|
| 摘要点击次数: 3418 |
| 全文下载次数: 2686 |
| 中文摘要: |
| 目的 评价放射性核素153Sm2乙二胺四甲基膦酸(153Sm EDTMP)治疗骨转移癌的疗效及其对造血功能的影响。方法 静脉注射153Sm EDTMP,每次0.5～1.5mCi kg体重。观察治疗前、后患者的生活质量、病灶及血细胞的变化。结果 患者疼痛完全缓解率(CR)32.5%(13/40);部分缓解率(PR)50%(20/40);疾病进展(PD)17.5%(7/40);总有效率82.5%。单一应用153Sm EDTMP,剂量≤1mCi的患者,对造血功能影响较小,一般于治疗后4周基本恢复。剂量>1mCi或与化疗联合应用的患者,对造血功能影响较大,需用G_CSF或输血(包括脐血)治疗,约治疗后6周才能恢复。结论 ①153Sm_EDTMP是比较理想的治疗多发性骨转移癌的放射性核素之一,具有控制病情发展、消除骨转移灶,改善患者生活质量的作用;②153Sm_EDTMP治疗后可使患者血象一过性降低。剂量>1mCi,连续治疗2次以上者可诱发全血减少;③脐血有恢复射线所致的造血功能损伤的作用。 |
| 英文摘要: |
| Objective To evaluate the clinical effect and side-effect of hemapoietic function of the patients with metastatic bone cancer treated by 153Sm-EDTMP. Methods 153Sm-EDTMP dose was 0.5-1.5 mCi/kg per time by intravenous, The changes of life quality, cancer size and hemapoietic function before and after treatment with 153Sm-EDTMP were evaluated. Results After treatment with 153Sm-EDTMP, 32.5%(13/40) patients with pain achieved complete response, 50%(20/40) patients had partial response, up progressives were observed in 17.5%(7/40) patients, total effective rate was 82.5%. With Dose<1 mCi, 153Sm-EDTMP administered alone affected more slightly the hemapoiteic fuction of patient's than that with dose >1 mCi, and recovered about four weeks after the treatment. With dose>1 mCi or 153Sm-EDTMP combinated with chmotherapy, the hemapoietic fuction was affected more obviouly. When WBC≤2×109/L, using G-CSF and cord blood to improve WBC level, patients recovered about six weeks after the treatment. Conclusion ① 153Sm-EDTMP treatment of metastatic bone cancer was effective, it can control focuses progress, eliminate metastatic bone focus and improve patient's life quality; ② 153Sm-EDTMP affected the hemapoietic function. With dose≥1 mCi, if 153Sm-EDTMP was administered continuously for more than two times for treatment, whole blood was deceased. ③cord blood can be used to improve hemapoietic function. ; |
| HTML 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|